We are live on ! Find out more
GRCE

Grace Therapeutics
GRCE

28 hedge funds and large institutions have $1.44M invested in Grace Therapeutics in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

458% more capital invested

Capital invested by funds: $258K → $1.44M (+$1.18M)

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

17% more funds holding

Funds holding: 24 → 28 (+4)

0.06% more ownership

Funds ownership: 0.03% → 0.09% (+0.06%)

Holders
28
Holders Change
+4
Holders Change %
+16.67%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
5
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$463K
2
VF
Virtu Financial
New York
+$133K
3
Citadel Advisors
Citadel Advisors
Florida
+$65.8K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$27.3K
5
HF
HRT Financial
New York
+$10.8K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$12K
2
AAS
Avantax Advisory Services
Texas
-$3K
3
SIG
Sargent Investment Group
Maryland
-$3K
4
TSS
Two Sigma Securities
New York
-$3K
5
Bank of America
Bank of America
North Carolina
-$485
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$625K +$463K +40,083 New
VF
2
Virtu Financial
New York
$224K +$133K +11,535 +412%
Bank of Montreal
3
Bank of Montreal
Ontario, Canada
$177K – – –
Two Sigma Advisers
4
Two Sigma Advisers
New York
$93K +$693 +60 +1%
Citadel Advisors
5
Citadel Advisors
Florida
$89K +$65.8K +5,699 New
OC
6
Oppenheimer & Co
New York
$73K +$7.27K +629 +16%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$56K +$27.3K +2,361 +185%
MMPW
8
Mitchell McLeod Pugh & Williams
Alabama
$15K – – –
HF
9
HRT Financial
New York
$14K +$10.8K +936 New
SIAP
10
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$13K – – –
Morgan Stanley
11
Morgan Stanley
New York
$13K +$92 +8 +1%
Millennium Management
12
Millennium Management
New York
$12K +$9.05K +783 New
PAG
13
Private Advisor Group
New Jersey
$10K – – –
LPL Financial
14
LPL Financial
California
$6K +$4.22K +365 New
Cetera Investment Advisers
15
Cetera Investment Advisers
Illinois
$5K +$3.62K +313 New
AWM
16
AE Wealth Management
Kansas
$4K +$3.17K +274 New
SFA
17
Sequoia Financial Advisors
Ohio
$3K – – –
Walleye Trading
18
Walleye Trading
New York
$3K – – –
FWM
19
Frontier Wealth Management
Missouri
$3K +$2.4K +208 New
Bank of America
20
Bank of America
North Carolina
$1K -$485 -42 -45%
ASN
21
Advisory Services Network
Georgia
$1K – – –
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
$1K – – –
PCIA
23
Prime Capital Investment Advisors
Kansas
$1K +$485 +42 New
FDCDDQ
24
Federation des caisses Desjardins du Quebec
Quebec, Canada
$633 -$35 -3 -7%
RE
25
RBC Europe
United Kingdom
$10 – – –
1
2

GRCE Hedge Fund Activity: Q4 2020 in Review

28 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q4 2020, worth a combined $1.44M — up 458% from $258K a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new GRCE positions and 6 closed out — a net gain of 4 holders — while 5 added to existing stakes and 2 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $463K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $12K sold.

  • 28 institutional investors held Grace Therapeutics (GRCE) as of Q4 2020, up from 24 in Q3 2020.
  • Funds reported $1.44M of Grace Therapeutics stock for Q4 2020, up 458% quarter-over-quarter.
  • 10 funds opened new Grace Therapeutics positions in Q4 2020 and 6 closed out, a net change of +4 holders.
  • The largest Grace Therapeutics buyer in Q4 2020 was Renaissance Technologies, an estimated $463K added.
  • The largest Grace Therapeutics seller in Q4 2020 was Susquehanna International Group, an estimated $12K sold.

Based on aggregated 13F filings for Q4 2020.